Relmada Therapeutics Cash Flow - Annual (OTCMKTS:RLMD)

Add to My Stocks
$1.14 $0.01 (0.87%) RLMD stock closing price Sep 21, 2018 (Closing)

The financial analysis of RLMD requires an investor to check the cash flows for Relmada Therapeutics. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Relmada Therapeutics profits and Relmada Therapeutics debt. This statement can tell if a company is running out of money while still being profitable and is useful in Relmada Therapeutics stock analysis. Relmada Therapeutics had a negative net income cash flow of $-6.28M for the latest 2017. This report is very useful in measuring the short term viability of a company. Relmada Therapeutics saw a outflow of $-0.04M from investing activities for 2017.

View details of Relmada Therapeutics cash flows for latest & last 10 financial years
show more
Fiscal year is Jul - Jun2017201620152014
Net Income Cash Flow
-6.28M-2.97M-20.8M-21.33M
Depreciation Depletion Amortization Cash-Flow----
Net Increase (Decrease) in Assets Liabilities-0.24M1.67M-1.12M-
Cash From (used in) Discontinued Operations----
Other Adjustments Net-0.01M-11.9M5.68M18.28M
Net Cash from (used by) Operating Activities
-6.46M-13.14M-16.22M-2.16M
Increase (Decrease) in Prop Plant And Equipment-0.04M-0.56M-0.02M-
Acquisition Disposition of Subsidiaires----
Increase (Decrease) in Investments----
Other Cash Inflow (Outflow) from Investment Activities----
Net Cash from (used by) Investment Activities
-0.04M-0.56M-0.02M-
Issuance (Purchase) of Equity Shares--13.44M24.22M
Issuance (Repayment) of Debt Securities----
Increase (Decrease) in Bank & Other Borrowings-0.27M-0.26M-0.29M-0.01M
Payment of Dividends & Other Cash Distributions----
Other Cash from (used by) Financing Activities----
Net Cash from (used by) Financing Activities
-0.27M-0.26M13.15M24.2M
Effect of Exchange Rate Changes on Cash----
Net Change in Cash & Cash Equivalents
-6.78M-13.96M-3.09M22.04M
Cash & Equivalents at Beginning of Year8.5M22.46M25.56M3.52M
Cash & Equivalents at Year End1.71M8.5M22.46M25.56M
All figures in USD. M: Millions of USD, B: Billions of USD.

Relmada Therapeutics stock comparison chart provides an easy way to compare the stock price with peers along with details of Relmada Therapeutics stock price history.
The statement of cash flows can be categorized into three main sections:

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that Relmada Therapeutics is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - Relmada Therapeutics stock price movement.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Relmada Therapeutics lost $-6.46M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash from investing stood at a negative value of $-0.04M for RLMD stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Relmada Therapeutics spent $-0.27M from financing activities, in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Relmada Therapeutics Cash Flow

Annual Cash Flow Statements For Relmada Therapeutics Peers

ACHIEVE LIFESCI cash flow, ALTIMMUNE INC cash flow, Bio-Path cash flow, Ohr Pharmaceuticals cash flow